Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) came under pressure in the premarket on Tuesday after the company’s Q1 2025 ...

Intraocular inflammation occurred more frequently with 8-mg aflibercept (Eylea) compared with what was observed in previous ...

Important Safety Information: EYLEA HD and EYLEA are administered via intravitreal injection. Patients should not use EYLEA HD if they have ocular or periocular infections, active intraocular ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period, reducing the number of injections by half ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the ...

EYLEA HD was developed to achieve comparable efficacy and safety to EYLEA, but with fewer injections. EYLEA HD is supported by a robust body of research and is currently approved in the U.S. to ...

EYLEA HD was developed to achieve comparable efficacy and safety to EYLEA, but with fewer injections. EYLEA HD is supported by a robust body of research and is currently approved in the U.S. to treat ...